Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Chaari, Mourad ^a,b   Ayadi, Ines ^b   Rousseau, Aurelie ^c   Lefkou, Eleftheria ^a   Van Dreden, Patrick ^d   Sidibe, Fatoumata ^a   Ketatni, Hela ^a   Galea, Vassiliki ^a   Khaterchi, Amir ^a   Bouzguenda, Racem ^b   Frikha, Mounir ^b   Ghorbal, Lilia ^b   Daoud, Jamel ^b   Kallel, Choumous ^b   Quinn, Martin ^a   Gligorov, Joseph ^b,c   Lotz, Pierre ^c   Hatmi, Mohamed ^e   Elalamy, Ismail ^a,c   Gerotziafas, Grigoris T ^a,c  

^a HÔPITAL TENON   (France)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c SORBONNE UNIVERSITÉ   (France)

^d Research and Development   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

Breast cancer; D Dimers; Microparticles; Risk assessment model; Thrombin generation; Venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; D DIMER; PHOSPHOLIPID; PROCOAGULANT; THROMBIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; BLOOD CLOTTING TIME; BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR RISK; CELL LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; METASTASIS; PLATELET MICROPARTICLE; RISK ASSESSMENT; AGED; BLOOD; BLOOD CLOTTING TEST; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; THROMBOPHILIA;

ADULT; AGED; BIOMARKERS; BLOOD COAGULATION TESTS; BREAST NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MIDDLE AGED; RISK FACTORS; THROMBIN; THROMBOPHILIA;

EID: 84924366874     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-991     Document Type: Article

References (45)

1. Trousseau A: Phlegmasia Alba Dolens. In Clinique Medicale de l'Hotel Dieu de Paris. Edited by: Trousseau A. Paris: Ballier; 1865:654-712.
2. Boulliaud M: De l'oblitération des veins et de son influence sur la formation des hydropisies partielles. Arch Gen Med 1823, 1:188-204.
3. Illtyd J, Matheson N: Thrombophlebitis in Cancer. The Practitioner. 1935.
4. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768. 10.1001/archinte.160.6.761
5. Blom JW, Doggen CJ, Osanto S, Rosendaal FR: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715-722. 10.1001/jama.293.6.715
6. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT: Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010, 103:947-953. 10.1038/sj.bjc.6605883
7. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007, 5:246-254.
8. Zwicker JI, Furie BC, Furie B: Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007, 62:126-136. 10.1016/j.critrevonc.2007.01.001
9. Ten Cate H, Falanga A: Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2008, 36:122-130.
10. Wun T, White RH: Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009,27(Suppl 1):63-74.
11. Lauw MN, van Doormaal FF, Middeldorp S, Buller HR: Cancer and venous thrombosis: current comprehensions and future perspectives. Semin Thromb Hemost 2013, 39:507-514. 10.1055/s-0033-1343891
12. Chew HK, Wun T, Harve DJ, Zhou H, White RH: Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007, 25:70-76.
13. Rickles FR, Levine MN: Epidemiology of thrombosis in cancer. Acta Haematol 2001, 106:6-12. 10.1159/000046583
14. Tran BH, Nguyen TJ, Hwang BH, Vidar EN, Davis GB, Chan LS, Woo K, Wong AK: Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast 2013, 22:444-448. 10.1016/j.breast.2013.04.018
15. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotziafas GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR: International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013, 11:56-70. 10.1111/jth.12070
16. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-4907. 10.1182/blood-2007-10-116327
17. Schaffner F, Ruf W: Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009, 29:1999-2004. 10.1161/ATVBAHA.108.177428
18. Nurden AT: Platelets, inflammation and tissue regeneration. Thromb Haemost 2011,105(Suppl 1):S13-S33.
19. Owens AP 3rd, Mackman N: Microparticles in hemostasis and thrombosis. Circ Res 2011, 108:1284-1297. 10.1161/CIRCRESAHA.110.233056
20. Rauch U, Nemerson Y: Circulating tissue factor and thrombosis. Curr Opin Hematol 2000, 7:273-277. 10.1097/00062752-200009000-00003
21. Butenas S, Orfeo T, Mann KG: Tissue factor activity and function in blood coagulation. Thromb Res 2008,122(Suppl 1):S42-S46.
22. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I: High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012, 97:1158-1164. 10.3324/haematol.2011.054718
23. Knowlson L, Bacchu S, Paneesha S, McManus A, Randall K, Rose P: Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 2010, 63:818-822. 10.1136/jcp.2010.076349
24. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I: Prediction of venous thromboembolism in cancer patients. Blood 2010, 116:5377-5382. 10.1182/blood-2010-02-270116
25. Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C: TNM Atlas. Guide Illustré de la Classification TNM/pTNM des Tumeurs Malignes. 4th edition. Paris: Springer-Verlag France; 1998.
26. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15. 10.1159/000071636
27. Robert S, Poncelet P, Lacroix R, Arnaud L, Giraudo L, Hauchard A, Sampol J, Dignat-George F: Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost 2009, 7:190-197. 10.1111/j.1538-7836.2008.03200.x
28. Trappenburg MC, van Schilfgaarde M, Bredewold EO, van Aalderen MC, Spronk HM, Ten Cate H, Leyte A, Terpstra WE: Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy. Thromb Res 2011, 127:363-369. 10.1016/j.thromres.2010.12.015
29. Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S: Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 2009, 56:479-484. 10.1016/j.eururo.2008.06.038
30. Varon D, Shai E: Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 2009, 8:237-241.
31. Rak J: Microparticles in cancer. Semin Thromb Hemost 2010, 36:888-906. 10.1055/s-0030-1267043
32. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, Spannagl M, Friese K, Reininger AJ: Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008, 100:663-669.
33. Tseng CC, Wang CC, Chang HC, Tsai TH, Chang LT, Huang KT, Leu S, Yen CH, Liu SF, Chen CH, Yang CT, Yip HK, Lin MC: Levels of circulating microparticles in lung cancer patients and possible prognostic value. Dis Markers 2013, 35:301-310.
34. Papageorgiou C, Van Dreden P, Marret E, Bonnet F, Robert F, Spyropoulos A, Galea V, Elalamy I, Hatmi M, Gerotziafas G: Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. Thromb Res 2013, 132:584-591. 10.1016/j.thromres.2013.07.005
35. Lechner D, Weltermann A: Chemotherapy-induced thrombosis: a role for microparticles and tissue factor? Semin Thromb Hemost 2008, 34:199-203. 10.1055/s-2008-1079261
36. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191. 10.1016/S0959-8049(02)00596-8
37. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I: Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna cancer and thrombosis study. J Clin Oncol 2011, 29:2099-2103. 10.1200/JCO.2010.32.8294
38. Pabinger I, Thaler J, Ay C: Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013, 122:2011-2018. 10.1182/blood-2013-04-460147
39. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Guadagni F, Roselli M: Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study. Support Care Cancer 2012, 20:2713-2720. 10.1007/s00520-012-1391-1
40. Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, Cavaliere F, Palmirotta R, Guadagni F: Impact of chemotherapy on activated protein C-dependent thrombin generation-association with VTE occurrence. Int J Cancer 2013, 133:1253-1258. 10.1002/ijc.28104
41. Mukherjee SD, Swystun LL, Mackman N, Wang JG, Pond G, Levine MN, Liaw PC: Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb 2010, 37:88-97.
42. Swystun LL, Mukherjee S, Liaw PC: Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011, 9:2313-2321. 10.1111/j.1538-7836.2011.04465.x
43. Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyák K, Tans G, Rosing J: Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003, 120:117-122. 10.1046/j.1365-2141.2003.03987.x
44. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002, 86:389-395. 10.1038/sj.bjc.6600069
45. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.